.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
QuintilesIMS
Deloitte
Baxter
AstraZeneca
Farmers Insurance
Colorcon
Accenture
Express Scripts

Generated: November 19, 2017

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR
TETRABENAZINE

« Back to Dashboard

Clinical Trial Listing

Trial ID Title Status Sponsor Phase Summary
NCT00219804 Efficacy and Safety of Tetrabenazine in ChoreaCompletedPrestwick PharmaceuticalsPhase 3 The primary objective of this study was to establish the absolute reduction of chorea in participants with Huntington's disease(HD) treated with tetrabenazine or placebo
NCT00362804 Tetrabenazine for Partial RespondersCompletedStanley Medical Research InstituteN/A Purpose of Study: A) To improve outcome in large population of antipsychotic patients with schizophrenia or schizoaffective who are only partial responders B) To increase understanding of pharmacology and mechanisms of action underlying antipsychotic effect Hypothesis/Objectives of the Study: Tetrabenazine, through its pre-synaptic action, should augment the post-synaptic effects of an antipsychotic. Background and Rationale for the study: Preliminary evidence that other amine-depleting agents e.g., reserpine, can induce such an effect
NCT00362804 Tetrabenazine for Partial RespondersCompletedCentre for Addiction and Mental HealthN/A Purpose of Study: A) To improve outcome in large population of antipsychotic patients with schizophrenia or schizoaffective who are only partial responders B) To increase understanding of pharmacology and mechanisms of action underlying antipsychotic effect Hypothesis/Objectives of the Study: Tetrabenazine, through its pre-synaptic action, should augment the post-synaptic effects of an antipsychotic. Background and Rationale for the study: Preliminary evidence that other amine-depleting agents e.g., reserpine, can induce such an effect
NCT00632645 Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and TiaprideRecruitingAssistance Publique - Hôpitaux de ParisPhase 3 Huntington's disease (HD) is autosomal dominant neurodegenerative disease, starting in average (with high variability) in the fourth decade. The disease progression is classically characterized by a cognitive deterioration (cortical-frontal dementia), motor disorders (associating chorea, dystonia and bradykinesia), psychiatric disturbances (combining depression and irritability) and metabolic disorder (cachexia). The disease is fatal within 15 to 20 years in most patients. HD has no cure. Neuroleptics are the main drug used and the only to demonstrate its efficacy on chorea in clinical trials. But neuroleptics have also beneficial and adverse effects on other disease characteristics (motor, psychiatric, cognitive or metabolic). Their profile between beneficial and adverse effects could be different according the neuroleptics and their classification. The aim of this study is to compare beneficial and adverse effects of 3 different neuroleptics in HD.
NCT00642057 Compassionate Use of Tetrabenazine in the Treatment of Abnormal MovementsAvailableChristine HunterN/A Although the results of studies looking at tetrabenazine have shown its effectiveness in the management of hyperkinetic(too much) movement disorders, it has not been made available in the U.S. The drug must be obtained from Cambridge Laboratories, the distributor, using an individual IND (#16,161). The cost of the drug is passed on to the patient. The purpose of the protocol is to provide an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).
NCT01133353 A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette's SyndromeWithdrawnValeant Pharmaceuticals International, Inc.Phase 2 The purpose of this clinical trial is to study the therapeutic effect of tetrabenazine MR in children with Tourette's Syndrome, as measured by the improvement in total tic score of the Yale Global Tic Severity Scale (YGTSS).
NCT01543321 Xenazine in Late Dyskinetic Syndrome With NeurolepticsRecruitingCentre Hospitalier Universitaire, AmiensPhase 3 Late dyskinetic syndrome with neuroleptics, or tardive dyskinesia, is the appearance of abnormal involuntary movements (AIM) in patients treated with antipsychotics for at least three months. This important public health issue arises for 15-20% of patients treated with neuroleptics, the most prescribed psychotropic drugs in mental disorders in France, and seriously impacts the patients' quality of life. In over 50% of cases, it is irreversible-that is to say that he will persist despite discontinuation of the offending drug. Risk factors have been described: the age and female gender are established, a higher dosage of antipsychotic, a long-term treatment, a psychiatric condition other than schizophrenia are likely risk factors, intermittent treatment, previous acute dyskinesia, neuroleptics or powerful, longer term use of corrective treatments including anticholinergics are still discussed. Apart from preventive treatment, which consists in using antipsychotics as being coerced, support is disappointing: the etiological treatment, which is to stop the offending antipsychotic, is effective only in less than 50% of cases, the syndrome is most often late irreversible. Must still have the possibility to interrupt the treatment, which is usually impossible in the risk of decompensation of the mental illness for which the neuroleptic was prescribed. Remains symptomatic treatment: functional neurosurgery is only for extreme cases, because it is not without risk, in terms of morbidity and mortality. So it's the medication that is most often offered: many drugs have been proposed, a direct result of the multiplicity of neurotransmitter systems implicated. However, in the vast majority of cases, this approach is disappointing not to say ineffective. The only exception is the tetrabenazine, marketed under the name of Xenazine®. Empirically, neurologists specializing in pathology of the movement are almost unanimous: its efficiency is very good, with good tolerance. Some preliminary studies have reinforced this impression. However, their level of evidence remains low and that is why the investigators propose to implement a prospective multicenter clinical trial, double-blind with placebo which will include two groups of 27 patients.
NCT01834911 Effect of Tetrabenazine on Stroop Interference in HDRecruitingNew York Medical CollegePhase 4 Tetrabenazine has been shown to improve gating of abnormal visual stimuli and improve postural stability in Huntington disease (HD) patients as measured by computerized dynamic posturography testing. This study aims to elucidate whether partial dopaminergic depletion via low dose tetrabenazine has a similar effect on masking out of abnormal visual stimuli on the Stroop interference test.
NCT01897896 Alternatives for Reducing Chorea in HDActive, not recruitingAuspex Pharmaceuticals, Inc.Phase 3 The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of SD-809 ER in subjects switching from tetrabenazine to SD-809 ER. In addition, the safety and tolerability of long term treatment with SD-809 ER will be assessed in "Switch" subjects as well as "Rollover" subjects completing a randomized, double blind, placebo controlled study of SD-809 ER,
NCT02509793 A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)RecruitingH. Lundbeck A/SPhase 4 The purpose of this research study is to see if tetrabenazine, which is commonly used to treat Huntington's Disease (HD), reduces the problems of impulsivity that are common in patients with HD. Investigators will also see how the medicine affects aspects of thinking and mood.
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Conditions

Condition Name

Condition Name for TETRABENAZINE
Intervention Trials
Huntington's Disease 2
Huntington Disease 2
Schizophrenia 2
Schizoaffective Disorder 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for TETRABENAZINE
Intervention Trials
Huntington Disease 5
Movement Disorders 2
Schizophrenia 2
Psychotic Disorders 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trial Locations

Trials by Country

Trials by Country for TETRABENAZINE
Location Trials
United States 29
Canada 3
France 3
Australia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for TETRABENAZINE
Location Trials
New York 2
Texas 2
Arkansas 1
Colorado 1
District of Columbia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress

Clinical Trial Phase

Clinical Trial Phase for TETRABENAZINE
Clinical Trial Phase Trials
Phase 4 2
Phase 3 4
Phase 2 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for TETRABENAZINE
Clinical Trial Phase Trials
Recruiting 5
Completed 3
Active, not recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors

Sponsor Name

Sponsor Name for TETRABENAZINE
Sponsor Trials
Canadian Network for Observational Drug Effect Studies, CNODES 1
Prestwick Pharmaceuticals 1
Centre Hospitalier Universitaire, Amiens 1
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for TETRABENAZINE
Sponsor Trials
Other 12
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Chinese Patent Office
Daiichi Sankyo
Baxter
QuintilesIMS
Citi
McKesson
Julphar
Deloitte
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot